Supported acquisition environment
Scanner manufacturers: All
exact submission · checked 2026-09-01Confirm currently supported software versions, protocols, and site-specific acquisition configurations.
FDA-cleared profile
Vital Images, Inc. · CT/CTA · FDA-cleared (510(k))
Authorized purpose: Non-invasive post-processing for brain perfusion that calculates CBF, CBV, bolus timing/TTP, and MTT.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Non-invasive post-processing for brain perfusion that calculates CBF, CBV, bolus timing/TTP, and MTT.
Evidence takeaway. Evidence from the reviewed source record: Software verification and validation, Bayesian algorithm testing, and external physician validation; no quantitative clinical performance metrics were reported.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Packet wording: "Vitrea CT Brain Perfusion is a noninvasive post-processing software that calculates cerebral blood flow (CBF), cerebral blood volume (CBV), local bolus timing (i.e., delay of tissue response, time to peak), and mean transit time (MTT) from dynamic CT image data." … "It displays time density curves, perfusion characteristics in perfusion and summary maps, as well as regions of interest and mirrored regions.". Read from the exact FDA decision document on 2026-11-14.
FDA packet input scope.
FDA packet output scope.
Packet wording: "Vitrea CT Brain Perfusion is intended for patients with suspected compromised or abnormal cerebral blood flow." … "Vitrea CT Brain Perfusion is a non-invasive post-processing application designed to evaluate areas of brain perfusion.". Read from the exact FDA decision document on 2026-11-14.
FDA packet intended-user statement.
Exact FDA limitation boundary.
Packet testing description, not clinical-performance evidence.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Packet testing description, not clinical-performance evidence.
This field has not been curated yet.
This field has not been curated yet.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Price not public here; enter your quote
Not verified: Pricing information is recorded but not verified against a resolving source.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Dynamic CT data acquired after contrast injection from patients with suspected abnormal cerebral blood flow.
Scope: Exact FDA submission. FDA packet input scope.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-15 · FDA K181247: Vitrea CT Brain Perfusion
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state the subject device's DICOM, PACS, RIS, or EHR interfaces. Confirm supported DICOM services and PACS, RIS, EHR, and interface versions with the vendor.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-11-14 ·
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-09 ·
Source context, not route validation: Perfusion maps, time-density curves, ROIs and mirrored ROIs, color-coded summaries, and 4D-DSA views.
Scope: Exact FDA submission. FDA packet output scope.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-15 · FDA K181247: Vitrea CT Brain Perfusion
Unresolved route: Perfusion maps, time-density curves, ROIs and mirrored ROIs, color-coded summaries, and 4D-DSA views.
Scope: Exact FDA submission. FDA packet output scope.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-15 · FDA K181247: Vitrea CT Brain Perfusion
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Vendor statement, not an attestation. The MDS2 names the Vitrea Advanced Visualization platform, not this specific application release; Canon Medical Informatics' Vitrea neuro/cardiac pages document CT Brain Perfusion as an application within that platform (applicant Vital Images, Inc. is Canon Medical Informatics' predecessor name for the Vitrea line). Exact-release scope is not established.
User qualification wording only; the summary specifies no training program or training offering for this device.
Scanner manufacturers: All
exact submission · checked 2026-09-01Confirm currently supported software versions, protocols, and site-specific acquisition configurations.
ACR AI Central provides an exact-submission model card for Vitrea CT Brain Perfusion; FDA labeling remains controlling for clinical use, limitations, and performance.
exact submission · checked 2026-09-09Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
FDA specifies dynamic contrast-enhanced CT; catalog uses CT/CTA as the CT bucket.
FDA packet brain-perfusion scope.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public price or quote for the exact K181247 configuration was established in this review.
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
The exact FDA decision document was reviewed on 2026-11-14 and does not state the subject device's DICOM, PACS, RIS, or EHR interfaces. Confirm supported DICOM services and PACS, RIS, EHR, and interface versions with the vendor.
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
9 sources - 3 history items
Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, output, limitations, anatomy, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: postmarketSafety
Scope: security
Scope: security
Regulatory record
510(k)
Research record
fda record reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Brainomix Limited
Authorized purpose: Brainomix 360 e-CTA analyzes adult CTA brain DICOM for vessel visualization and post-processing, including MCA vessel-density asymmetry, contrast/phase context, overlays, and MIP views, for trained clinical review; it is not for mobile diagnosis and its vessel-density asymmetry ratio is limited to the MCA region.
Brainomix Limited
Authorized purpose: Assists clinician assessment of brain abnormalities and ischemic injury by generating an automated ASPECTS score for known MCA/ICA occlusion cases.
GE Medical Systems SCS
Authorized purpose: Analyzes CT data to display head and neck vasculature and CT perfusion to generate regional blood-flow, blood-volume, mean-transit-time, and capillary-permeability images.
Icometrix NV
Authorized purpose: Analyzes and communicates dynamic CT-perfusion datasets.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history